Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials ASCO Guidelines provide recommendations with comprehensive ...
More evidence points to the benefits of germline genetic testing for patients with various cancers. Such testing can identify mutations that may warrant a change of treatment and allow trying a ...
Precision medicine in prostate cancer utilizes genetic testing to identify patients for PARP inhibitor treatment, enhancing personalized care. Genetic testing, including germline and somatic, is ...
BALTIMORE, Nov. 13, 2025 (GLOBE NEWSWIRE) -- The Urology Care Foundation (UCF), the official foundation of the American Urological Association (AUA), and the Prostate Cancer Foundation (PCF) today ...
The global statistics are terrifying. Prostate cancer is the fourth most common cancer in all populations, the second most common cancer among men worldwide, and ranks first in Europe, where a third ...
New Publication Shows PROSTOX™ ultra Test Delivers Significant Health System Cost Savings and Quality-of-Life Gains for Prostate Cancer Patients Undergoing Radiation Therapy MiraDx, a molecular ...
PSA stands for prostate-specific antigen, a substance naturally produced in prostate tissue. A small amount of PSA regularly sneaks into the bloodstream, and low blood concentration is considered ...
Collaboration brings whole-exome based hereditary cancer insights to urologists and their patients by offering it alongside Veracyte's Decipher Prostate Test The partnership was also highlighted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results